BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/30/2015 1:35:00 PM | Browse: 1095 | Download: 1314
 |
Received |
|
2014-08-26 19:55 |
|
Peer-Review Started |
|
2014-08-28 08:13 |
|
To Make the First Decision |
|
2014-09-15 16:08 |
|
Return for Revision |
|
2014-09-28 09:27 |
|
Revised |
|
2014-10-14 15:46 |
|
Second Decision |
|
2014-11-19 08:42 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2014-12-01 13:39 |
|
Articles in Press |
|
2014-12-01 14:00 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2015-01-12 16:49 |
|
Typeset the Manuscript |
|
2015-05-15 17:27 |
|
Publish the Manuscript Online |
|
2015-05-30 13:32 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu Jin, Yan Lin, Lian-Jie Lin and Chang-Qing Zheng |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Science and Technology Program of Liaoning Province |
2013225303 |
|
| Corresponding Author |
Chang-Qing Zheng, MD, Department of Gastroenterology, Shengjing Hospital of China Medical University, Huaxiang Branch, No. 9 Huaxiang Road, Tiexi District, Shenyang 110021, Liaoning Province, China. zhengchangqing88@163.com |
| Key Words |
Inflammatory bowel disease; Ulcerative colitis; Vedolizumab; MLN-002; Meta-analysis |
| Core Tip |
Studies have suggested that vedolizumab may be effective in reducing intestinal inflammation in patients with ulcerative colitis (UC). This meta-analysis including three randomized controlled trials showed that treatment with vedolizumab results in significantly higher clinical response and remission rates than placebo in patients with UC. Importantly, serious adverse events were not more common in vedolizumab-treated patients than control patients. This analysis supports the use of vedolizumab for the treatment of UC. |
| Publish Date |
2015-05-30 13:32 |
| Citation |
Jin Y, Lin Y, Lin LJ, Zheng CQ. Meta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitis. World J Gastroenterol 2015; 21(20): 6352-6360 |
| URL |
http://www.wjgnet.com/1007-9327/full/v21/i20/6352.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v21.i20.6352 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
